Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on β-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells by Prasanthi, Jaya RP et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Molecular Neurodegeneration
Open Access Research article
Differential effects of 24-hydroxycholesterol and 
27-hydroxycholesterol on β-amyloid precursor protein levels and 
processing in human neuroblastoma SH-SY5Y cells
Jaya RP Prasanthi, Amber Huls, Sarah Thomasson, Alex Thompson, 
Eric Schommer and Othman Ghribi*
Address: Department of Pharmacology, Physiology and Therapeutics, University of North Dakota School of Medicine and Health Sciences, Grand 
Forks, North Dakota 58202, USA
Email: Jaya RP Prasanthi - jrantham@medicine.nodak.edu; Amber Huls - amber.huls@und.nodak.edu; 
Sarah Thomasson - sarah.thomasson@und.nodak.edu; Alex Thompson - alex.thompson@und.nodak.edu; 
Eric Schommer - eric.schommer@und.nodak.edu; Othman Ghribi* - oghribi@medicine.nodak.edu
* Corresponding author    
Abstract
Background: Activation of the liver × receptors (LXRs) by exogenous ligands stimulates the
degradation of β-amyloid 1–42 (Aβ42), a peptide that plays a central role in the pathogenesis of
Alzheimer's disease (AD). The oxidized cholesterol products (oxysterols), 24-hydroxycholesterol
(24-OHC) and 27-hydroxycholesterol (27-OHC), are endogenous activators of LXRs. However,
the mechanisms by which these oxysterols may modulate Aβ42 levels are not well known.
Results: We determined the effect of 24-OHC and/or 27-OHC on Aβ generation in SH-SY5Y
cells. We found that while 27-OHC increases levels of Aβ42, 24-OHC did not affect levels of this
peptide. Increased Aβ42 levels with 27-OHC are associated with increased levels of β-amyloid
precursor protein (APP) as well as β-secretase (BACE1), the enzyme that cleaves APP to yield Aβ.
Unchanged Aβ42 levels with 24-OHC are associated with increased levels of sAPPα, suggesting
that 24-OHC favors the processing of APP to the non-amyloidogenic pathway. Interestingly, 24-
OHC, but not 27-OHC, increases levels of the ATP-binding cassette transporters, ABCA1 and
ABCG1, which regulate cholesterol transport within and between cells.
Conclusion: These results suggest that cholesterol metabolites are linked to Aβ42 production.
24-OHC may favor the non-amyloidogenic pathway and 27-OHC may enhance production of Aβ42
by upregulating APP and BACE1. Regulation of 24-OHC: 27-OHC ratio could be an important
strategy in controlling Aβ42 levels in AD.
Background
Cholesterol-enriched diets cause hypercholesterolemia
and lead to increased levels of β-amyloid (Aβ) peptide in
rabbit brain [1-3]. Because Aβ accumulation is a patholog-
ical hallmark of Alzheimer's disease (AD), high blood
cholesterol levels may be a risk factor for AD in humans.
However, because cholesterol homeostasis in the brain is
regulated through de novo synthesis, with no or very poor
transfer from the peripheral circulation due to the imper-
meability of the blood brain barrier (BBB) to plasma lipo-
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proteins [4], the mechanisms by which cholesterol in the
peripheral system increases Aβ levels in the brain are not
fully understood.
In contrast to cholesterol, the side-chain oxidized oxyster-
ols, 24-hydroxycholesterol (24-OHC) and 27-hydroxyc-
holesterol (27-OHC), have the ability to cross lipophilic
membranes into and out of the brain [5,6]. Increased cho-
lesterol levels in plasma may result in increased levels of
oxysterols and subsequent increased entrance of these
compounds into the brain. Abnormal levels of these oxys-
terols in the brain might therefore be the trigger of
increased Aβ production. Furthermore, oxysterols are
endogenous activators of liver × activated receptors
(LXRs), which have been shown to play a role in regula-
tion of Aβ in the brain by mechanisms involving choles-
terol transporters [7,8]. Although 24-OHC and 27-OHC
have been demonstrated to modulate Aβ levels in primary
cortical neurons [9], the mechanisms by which these oxys-
terols regulate Aβ production are not fully understood.
The aim of our study is to determine the extent to which
and mechanisms by which 24-OHC and/or 27-OHC
modulate Aβ generation in human neuroblastoma cells.
Aβ is generated from β-amyloid precursor protein (APP)
through an initial cleavage with the β-secretase, BACE1
[10-12]. Two forms of Aβ, a major species Aβ40 and a
minor species Aβ42, are produced under physiological
conditions. Cleavage of APP by α-secretase, on the other
hand, leads to a non-amyloidogenic pathway [10]. We
therefore determined the effect of the two oxysterols on
levels of Aβ40, Aβ42, APP, secreted APP after α-secretase
cleavage (sAPPα), and BACE1. We have also measured the
effects of the oxysterols on levels of the ATP-binding cas-
sette transporters ABCA1 and ABCG1, which regulate cho-
lesterol transport and Aβ levels in cells.
Results
27-OHC, but not 24-OHC, increases Aβ42 levels
Human neuroblastoma SH-SY5Y cells were treated with 5,
10 and 25 μM of 24-OHC, 27-OHC, or a mixture of 24-
OHC and 27-OHC, and Aβ42 levels were determined
with ELISA. ELISA measurements showed that treatment
with 5, 10 or 25 μM 24-OHC did not induce significant
changes in secreted Aβ42 levels compared to levels in
medium of untreated cells (Fig. 1a). Conversely to 24-
OHC, treatment with 5, 10 or 25 μM 27-OHC led to a sub-
stantial increase in Aβ42 levels (Fig. 1b). Treatment with a
mixture of 24-OHC + 27-OHC did not induce significant
changes in the levels of Aβ42 compared to levels from
untreated cells or cells treated with 27-OHC (Fig. 1c).
These results suggest that, although it doesn't reduce Aβ42
levels per se, 24-OHC, when added to 27-OHC, prevents
the 27-OHC-induced significant increase in Aβ42 levels.
27-OHC, but not 24-OHC, increases levels of secreted  Aβ42 Figure 1
27-OHC, but not 24-OHC, increases levels of 
secreted Aβ42. While treatment with 5, 10 and 25 μM 24-
OHC did not alter Aβ42 levels (a), treatment with 5, 10 and 
25 μM 27-OHC significantly increased levels of Aβ42 com-
pared to levels in medium of untreated cells (b). There was 
no difference in Aβ42 levels between untreated cells and 
cells treated with a mixture of 24-OHC + 27-OHC (c). **p < 
0.01 (One way ANOVA followed by Dunnett's multiple com-
parison test).Molecular Neurodegeneration 2009, 4:1 http://www.molecularneurodegeneration.com/content/4/1/1
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27-OHC increases levels of APP and BACE1
In order to determine potential mechanisms involved in
27-OHC-induced increase in Aβ42 levels, we examined
first the effects of 24-OHC and 27-OHC on levels of APP
and BACE1. We chose to carry out our experiments with a
concentration of 10 μM 24-OHC or 27-OHC. At 10 μM/
mL concentration, 24-hydroxycholesterol has been
shown to increase APP gene expression in human neuro-
nal cells [13] and 27-hydroxycholesterol has been shown
to inhibit neutral sphingomyelinase in human endothe-
lial cells [14]. Western blot (Fig. 2a) and densitometric
(Fig. 2b) analyses show the effect of 24-OHC, 27-OHC, or
a mixture of 24-OHC + 27-OHC on levels of APP and
BACE1. There was a significant increase in APP levels fol-
lowing treatment with 27-OHC. Treatment with 24-OHC
or with a mixture of 24-OHC + 27-OHC did not statisti-
cally increase APP levels. Increase in APP levels with 27-
OHC was associated with an increase in BACE1 levels.
Treatment with 24-OHC did not significantly alter BACE1
levels. The mixture of 24-OHC + 27-OHC increased
BACE1 levels significantly, indicating that 24-OHC does
not reverse the effects of 27-OHC on BACE1 levels. These
results suggest that 27-OHC-induced increase in levels of
APP and BACE1 favors the amyloidogenic pathway that
leads to increased Aβ42 production.
The immunofluorescence imaging (Fig. 3) showed a
reduced immunoreactivity to 6E10, an antibody that
detects full length APP as well as Aβ, in cells treated with
24-OHC in comparison to control cells. A substantial
increase in 6E10 staining was observed in cells with 27-
OHC compared to control cells or cells treated with 24-
OHC. In cells treated with a mixture of 24-OHC+27-
OHC, the intensity of the immunoreactivity to 6E10 anti-
body appears similar to that in control cells. These results
are in accordance with the Western blot data showing
increased APP and Aβ42 levels with 27-OHC compared to
treatment with 24-OHC.
24-OHC increases processing of APP via the non-
amyloidogenic pathway
Extracellular sAPPα levels were determined with Western
blot analysis in cell medium of control and of cells treated
with 24-OHC, 27-OHC, and 24-OHC+27-OHC. Treat-
ment with 24-OHC led to a substantial increase in sAPPα
levels (Fig. 4a and 4b). No significant changes in sAPPα
levels were observed in cells treated with 27-OHC or with
a mixture of 24-OHC+27-OHC when compared to con-
trol cells (Fig. 4a and 4b). These results suggest that 24-
OHC favors the processing of APP via the non-amyloidog-
enic pathway that precludes Aβ42 production.
To determine whether increased Aβ42 levels following
treatment with 27-OHC is associated with reduced levels
of Aβ40, the most abundant Aβ species in normal brain,
Aβ40 levels in the medium were measured using ELISA.
None of the 24-OHC, 27-OHC and 24-OHC + 27-OHC
treatments altered Aβ40 levels (Fig. 4c). These results sug-
gest that the increase in Aβ42 we found with 27-OHC
originates from increased processing of APP by BACE1
and not from shift of APP processing from Aβ40 to Aβ42.
Collectively, these results demonstrate that 24-OHC
favors the non-amyloidogenic pathway while 27-OHC
enhances the amyloidogenic pathway.
24-OHC, but not 27-OHC, increases ABCA1 and ABCG1 
levels
We also determined the effect of treatment with 24-OHC
and 27-OHC on ABCG1 and ABCA1, two cholesterol
27-OHC, but not 24-OHC, increases levels of APP and  BACE1 Figure 2
27-OHC, but not 24-OHC, increases levels of APP 
and BACE1. Representative Western blots (a) and densito-
metric (b) analysis demonstrating increased levels of APP 
with 27-OHC. No changes were found in levels of APP with 
24-OHC or 24-OHC+ 27-OHC treatment. BACE1 levels 
were unchanged with 24-OHC treatment but significantly 
increased with 27-OHC or a mixture of 24-OHC + 27-
OHC. *p < 0.05, **p < 0.01 (One way ANOVA followed by 
Dunnett's multiple comparison test).Molecular Neurodegeneration 2009, 4:1 http://www.molecularneurodegeneration.com/content/4/1/1
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Immunofluorescence staining of APP and Aβ increases with 27-OHC Figure 3
Immunofluorescence staining of APP and Aβ increases with 27-OHC. Immunostaining for APP and Aβ showed a 
decreased immunoreactivity to 6E10 antibody (green) in cells treated with 24-OHC compared treatment with 27-OHC. The 
immunoreactivity for 6E10 antibody in cells treated with a mixture of 24-OHC + 27-OHC is similar to that observed in control 
cells. DAPI (blue) was used as a nuclear counterstain. Bar 20 μm.Molecular Neurodegeneration 2009, 4:1 http://www.molecularneurodegeneration.com/content/4/1/1
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transporters that may be involved in APP processing and
Aβ production. Western blot (Fig. 5a) and densitometric
(Fig. 5b) analysis show the effect of 24-OHC, 27-OHC, or
a mixture of 24-OHC + 27-OHC on levels of ABCG1 and
ABCA1. Treatment with 24-OHC significantly increases
levels of ABCG1 and ABCA1. Neither 27-OHC nor a mix-
ture of 24-OHC + 27-OHC significantly altered ABCG1
and ABCA1 levels. These results suggest that regulation of
ABCG1 and ABCA1 levels with 24-OHC may be involved
in the processing of APP to the non-amyloidogenic path-
way.
Discussion
In this study, we demonstrated that 27-OHC favors the
amyloidogenic pathway which leads to increased Aβ42
levels. Interestingly, levels of Aβ42 in cells treated with a
mixture of 24-OHC + 27-OHC were similar to control lev-
els, suggesting that 24-OHC opposes the increase in Aβ
levels triggered by 27-OHC treatment. These effects on
Aβ42 may result from differential actions of 24-OHC and
27-OHC on APP levels and processing as 27-OHC, but
not 24-OHC, increases levels of APP and BACE1. A previ-
ous study has also shown that 24-OHC increases the activ-
ity of the non-amyloidogenic pathway [15], and we have
recently shown that 27-OHC increases Aβ aggregation in
organotypic slices from adult rabbit hippocampus [16].
Abnormalities in cholesterol metabolism in the blood
may be important in the pathogenesis of AD (see for
review [17]); however, the link between hypercholestero-
lemia and cerebral levels of Aβ is still obscure. Cholesterol
is oxidized to 24-OHC and 27-OHC by the enzymes cho-
lesterol 24-hydroxylase (CYP46A1) and cholesterol 27-
24-OHC increases processing of APP via the non-amyloidog- enic pathway Figure 4
24-OHC increases processing of APP via the non-
amyloidogenic pathway. Western blot (a) and densito-
metric analyses (b) demonstrating increased levels of sAPPα 
in medium of 24-OHC-treated cells. Treatment with 27-
OHC or a mixture of 24-OHC + 27-OHC did not influence 
sAPPα levels. Levels of Aβ40 were not affected by treatment 
with 24-OHC, 27-OHC, or a mixture of 24-OHC + 27-
OHC compared to levels in control cells (c). *p < 0.05 (One 
way ANOVA followed by Dunnett's multiple comparison 
test).
Treatment with 24-OHC, but not with 27-OHC, increased  ABCA1 and ABCG1 levels Figure 5
Treatment with 24-OHC, but not with 27-OHC, 
increased ABCA1 and ABCG1 levels. Representative 
Western blots (a) and densitometric analysis (b) showing 
increased levels ABCG1 and ABCA1 with 24-OHC treat-
ment. Treatments with 27-OHC or with a mixture of 24-
OHC + 27-OHC did not significantly change ABCA1 and 
ABCG1 levels. *p < 0.05 (One way ANOVA followed by 
Dunnett's multiple comparison test).Molecular Neurodegeneration 2009, 4:1 http://www.molecularneurodegeneration.com/content/4/1/1
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hydroxylase (CYP27A1) respectively. While 24-OHC is
primarily found in the brain, the amount of 27-OHC is
lower in the brain and higher in peripheral circulation
[5,6,18]. 27-OHC has the ability to cross the BBB to reach
the brain [6]. It may be possible that high blood choles-
terol levels are associated with increased turn-over of cho-
lesterol to 27-OHC, a condition that may enhance entry of
excess 27-OHC into the brain. High levels of 27-OHC in
the brain may therefore be a mechanism by which high
cholesterol levels in the blood induce AD-like pathologi-
cal hallmarks in the brain. Also, reduced levels of 24-OHC
in the brain may possibly lead to generation of AD pathol-
ogy. Indeed, it has been shown that levels of 24-OHC
were decreased and levels of 27-OHC were increased in
brains from AD subjects as well as in APP Tg mice for AD
[5]. Plasma and cerebrospinal fluid levels of 24-OHC were
also shown to be higher in early AD and vascular demen-
tia patients in comparison with age-matched controls [19-
21]
The cholesterol transporter ABCA1 has been shown to be
targeted by oxysterols and linked to Aβ production.
ABCA1 suppressed Aβ generation [22] and deletion of
ABCA1 led to increased Aβ deposition [23]. A previous
study has shown that both 24-OHC and 27-OHC dose
dependently increase ABCA1 levels [9]. We demonstrated
here an increase in levels of the cholesterol transporters
ABCA1 with 24-OHC but not with 27-OHC. This discrep-
ancy may be due to differences in the cell system used.
Effects of 24-OHC and 27-OHC on ABCG1, another cho-
lesterol transporter, are less known. One study demon-
strated that 24-OHC up-regulates LXR-mediated ABCG1
expression [24]. We demonstrate here that 24-OHC, but
not 27-OHC, increases levels of ABCG1. The increase in
levels of ABCA1 and ABCG1 is associated with the lower
levels of Aβ42 in our study. The effects of 24-OHC on
these cholesterol transporters may contribute to the low-
ering effects by this oxysterol on 27-OHC-induced
increase in Aβ42 levels. Conversely, the increase in Aβ42
levels we demonstrated with 27-OHC may be due at least
in part to unchanged levels of ABCA1 and ABCG1.
Conclusion
The present study suggests that 27-OHC increases the
accumulation of Aβ by mechanisms that may involve
increased processing of APP by BACE1, independently of
ABCA1 and ABCG1 expression. Conversely, 24-OHC
increases APP processing through the non-amyloidogenic
α-secretase pathway, and increases levels of ABCA1 and
ABCG1. Further studies are warranted to determine the
effect of 24-OHC on Aβ levels in cells overexpressing Aβ
or in animal models that exhibit Aβ accumulation. As LXR
is the common receptor for 24-OHC and 27-OHC, their
differential effects on APP levels and processing may be
related to factors other than LXR activation.
Methods
Cell culture reagents
Purified 24-OHC was obtained from Biomol Interna-
tional (Plymouth Meeting, PA) and 27-OHC from Medi-
cal Isotopes, Inc (Pelham, NH). Stock solutions of 24-
OHC and 27-OHC were prepared in ethanol and stored at
-70°C. All cell culture reagents were obtained from Invit-
rogen.
Cell culture treatment with 24-OHC, 27-OHC, and 24-
OHC+27-OHC
Human neuroblastoma SH-SY5Y cells were cultured in
25-cm2  cell culture flasks using Dulbecco's modified
Eagle's medium: Ham's F12 with Glutamax (DMEM:F12;
1:1; v/v) and 10% FBS. When the cells reached 80% con-
fluence, they were incubated for 24 h at 37°C in DMEM:
F12 with vehicle (ethanol), 24-OHC, 27-OHC, or a mix-
ture (1:1) of 24-OHC and 27-OHC. Cells incubated with
vehicles were used as a control.
Quantification of secreted Aβ levels
Following treatments, the culture medium was collected,
supplemented with protease and phosphatase inhibitors
cocktail, and centrifuged at 16,000 × g for 5 min at 4°C.
100 μl of supernatant was used for Aβ40 and Aβ42 quan-
tification by colorimetric sandwich ELISA (Covance, Den-
ver, PA) according to the manufacturer's protocol.
Treatments were performed in triplicate, and the quantity
of Aβ in each sample was measured in duplicate and
expressed as mean ± standard error for the samples. Aβ40
and Aβ42 levels are expressed in pg/ml.
Western blot analysis
Control, 24-OHC, 27-OHC, and 24-OHC + 27-OHC
treated cells were lysed with a protein extraction reagent
(M-PER; Thermo Scientific, Rockford, IL). For sAPPα
immunoprecipitation procedure prior to Western blot-
ting, media samples were incubated at 4°C overnight with
sAPPα antibody (2B3 clone, IBL-America, Minneapolis,
MN) using the Catch and Release Reversible Immunopre-
cipitation System (Millipore, Billerica, MA). Protein con-
centrations were determined with the BCA protein assay
reagent by standard protocol. Proteins were separated in
SDS-PAGE gels, transferred to a polyvinylidene difluoride
membrane (Millipore, Bedford, MD) and incubated with
antibodies to APP (1:1000, Chemicon International,
Temecula, CA), sAPPα (1:100), BACE1 (1:100, Chemicon
International, Temecula, CA), ABCG1 (1:100, Novus Bio-
logicals, Littleton, CO), and ABCA1 (1:100, Neuromics,
Edina, MN). β-actin was used as gel-loading control. The
blots were developed with enhanced chemiluminiscence
(Immmun-star HRP chemiluminiscent kit, Biorad, Her-
cules, CA). The results are quantified by densitometry and
represented as total integrated densitometric values.Molecular Neurodegeneration 2009, 4:1 http://www.molecularneurodegeneration.com/content/4/1/1
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Confocal microscopy
The immunostaining with 6E10 for detection of Aβ in
control, 24-OHC, 27-OHC, and 24-OHC +27-OHC
treated cells was carried out using confocal microscopy.
The cells were fixed with paraformaldehyde, blocked with
5% normal goat serum, and reacted overnight at 4°C with
6E10 antibody (1:250, Signet laboratories Inc., Dedham,
MA). Cells were then washed and incubated with second-
ary antibodies conjugated to Alexa fluor-488 (Molecular
Probes, Inc., Eugene, OR) for one hour at room tempera-
ture in the dark and washed with PBS. The cells were
mounted with Vectasheild containing DAPI (Vector labo-
ratories, Inc., Burlingame, CA). The cells were visualized
with a Zeiss LSM 510 META confocal system coupled to a
Zeiss Axiophot 200 inverted epifluorescence microscope.
Statistical Analysis
Data was analyzed for statistical significance using analy-
sis of variance (ANOVA) followed by Dunnett's multiple
comparison test with GraphPad Prism software 4.01. All
values obtained from three different experiments were
expressed as mean value ± SEM
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